Skip to main content

CSL to Acquire Vifor Pharma, a Leader in Kidney Care

A Swiss company, Vifor, prides itself on "helping patients lead better, healthier lives" and also specializes in iron deficiency and cardio-renal therapies.

Vifor Pharma logo with blue inverted triangle

CSL Limited, parent company to CSL Behring, recently announced its intent to acquire Vifor Pharma, a global specialty pharmaceutical company with leadership positions in iron deficiency, nephrology (kidney care) and cardio-renal therapies.

Headquartered in St. Gallen, Switzerland, Vifor’s mission is "helping patients lead better, healthier lives." As an organization driven by its promise to patients and to protect human health, CSL has a complementary and compatible vision, company officials told investors. With its scale and R&D resources, CSL seeks to expand delivery of Vifor products to patients globally.

“Vifor Pharma enhances CSL’s patient focus and ability to protect the health of those facing a range of rare and serious medical conditions,” CSL CEO and Managing Director Paul Perreault said in a statement. “Vifor Pharma will also expand our presence in the rapidly growing nephrology market, while giving us the opportunity to leverage our complementary scientific expertise.”

CSL, a global biotech with R&D and manufacturing capabilities in multiple locations worldwide, specializes in medicines to treat serious and rare diseases and vaccines to prevent influenza.

Since 1949, the company has had a presence in Switzerland, where it currently has a team of more than 1,800 people on the ground in R&D, manufacturing and other operations.

Learn more about the announced acquisition.